A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer
- PMID: 24332948
- DOI: 10.1016/j.ejso.2013.11.012
A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer
Abstract
Background: The prognostic role of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 in non-small-cell lung cancer (NSCLC) remains controversial. To clarify its impact on survival, we performed a meta-analysis to quantitatively assess STAT3 and phospho-STAT3 expression on the prognosis of NSCLC.
Methods: Published studies were identified using a systematic and thorough literature search. To be eligible, a study had to investigate STAT3 or phospho-STAT3 expression rates of NSCLC patients in different characteristics and provide patient survival data.
Results: A total of 17 retrospective trials were chosen for meta-analysis, including 1793 patients. The estimated pooled log HR (0.67, 95% CI: 0.57-0.77) of 9 trials (STAT3: log HR 0.71, 95% CI 0.38-1.04; phospho-STAT3: log HR 0.67, 95% CI 0.56-0.77) for NSCLC was statistically significant (P < 0.0001), suggesting that high STAT3 or phospho-STAT3 expression is a strong predictor of poor prognosis among patients with NSCLC. For the risk factors, pooled analysis of patients with STAT3 positivity, demonstrated a statistically significant OR (3.82, 95% CI: 2.37-6.16) between poorly differentiated carcinoma and well-moderately, OR (5.68, 95% CI: 3.16-10.21) between stage III-IV patients and stage I-II patients, and OR (3.41, 95% CI: 2.12-5.49) between patients with lymph node metastasis and patients without lymph node metastasis. However, pooled analysis of patients with phospho-STAT3 positivity only demonstrated a statistically significant OR (4.51, 95% CI: 1.57-12.96) between poorly differentiated carcinoma and well-moderately (P < 0.05).
Conclusions: High STAT3 or phospho-STAT3 expression is a strong predictor of poor prognosis among patients with NSCLC. The conclusion should be confirmed by large prospective studies with long-term follow-up.
Keywords: Meta-analysis; Non-small-cell lung cancer; Phosphorylated STAT3; Prognosis; Signal transducer and activator of transcription 3 (STAT3); Survival.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.Eur J Surg Oncol. 2012 Jun;38(6):523-30. doi: 10.1016/j.ejso.2012.02.180. Epub 2012 Mar 21. Eur J Surg Oncol. 2012. PMID: 22440742
-
Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.Pathol Res Pract. 2013 Aug;209(8):490-4. doi: 10.1016/j.prp.2013.04.018. Epub 2013 Jun 6. Pathol Res Pract. 2013. PMID: 23827213
-
[Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].Dtsch Med Wochenschr. 2006 Nov 24;131(47):2643-8. doi: 10.1055/s-2006-956268. Dtsch Med Wochenschr. 2006. PMID: 17109272 German.
-
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.Int J Clin Exp Pathol. 2014 Sep 15;7(10):6694-704. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25400749 Free PMC article. Review.
-
Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis.Interact Cardiovasc Thorac Surg. 2015 Jul;21(1):21-7. doi: 10.1093/icvts/ivv082. Epub 2015 Apr 15. Interact Cardiovasc Thorac Surg. 2015. PMID: 25883247 Review.
Cited by
-
Effusanin B Inhibits Lung Cancer by Prompting Apoptosis and Inhibiting Angiogenesis.Molecules. 2023 Nov 21;28(23):7682. doi: 10.3390/molecules28237682. Molecules. 2023. PMID: 38067413 Free PMC article.
-
CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition.Aging (Albany NY). 2024 Sep 10;16(17):12277-12292. doi: 10.18632/aging.206086. Epub 2024 Sep 10. Aging (Albany NY). 2024. PMID: 39264588 Free PMC article.
-
Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models.Cancers (Basel). 2020 May 19;12(5):1283. doi: 10.3390/cancers12051283. Cancers (Basel). 2020. PMID: 32438613 Free PMC article.
-
Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments.Acta Pharmacol Sin. 2018 Mar;39(3):425-437. doi: 10.1038/aps.2017.99. Epub 2017 Nov 9. Acta Pharmacol Sin. 2018. PMID: 29119966 Free PMC article.
-
STAT3/p-STAT3 expression is correlated with clinicopathological characteristics and prognosis in non-small cell lung cancer.Histol Histopathol. 2025 Jun;40(6):901-909. doi: 10.14670/HH-18-827. Epub 2024 Oct 3. Histol Histopathol. 2025. PMID: 39468938
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous